{
  "run_id": "run_06",
  "question": "What is the comparative effectiveness of SGLT2 inhibitors versus GLP-1 receptor agonists for cardiovascular outcomes in type 2 diabetes?",
  "status": "completed",
  "status_reason": "technically_complete",
  "disclaimer": "⚠️ This report is machine-generated by CDR (Clinical Deep Research). It is NOT medical advice and should NOT be used for clinical decision-making. All findings require independent verification by qualified professionals. See DISCLAIMER.md for full terms.",
  "timestamp": "2026-02-19T15:46:00Z",
  "pico": {
    "population": "patients with type 2 diabetes",
    "intervention": "SGLT2 inhibitors",
    "comparator": "GLP-1 receptor agonists",
    "comparator_source": "user_specified",
    "outcome": "cardiovascular outcomes",
    "study_types": [
      "rct"
    ]
  },
  "prisma_counts": {
    "records_identified": 15,
    "records_from_pubmed": 15,
    "records_from_clinical_trials": 0,
    "records_from_other": 0,
    "duplicates_removed": 0,
    "records_screened": 15,
    "records_excluded_screening": 0,
    "records_excluded": 7,
    "screening_exclusion_reasons": {},
    "reports_sought": 8,
    "reports_not_retrieved": 0,
    "reports_assessed": 8,
    "reports_excluded": 0,
    "records_excluded_enforcement": 0,
    "enforcement_exclusion_reasons": {},
    "studies_included": 8,
    "exclusion_reasons": {
      "study_type_mismatch": 7
    }
  },
  "study_count": 8,
  "claim_count": 3,
  "snippet_count": 16,
  "claims": [
    {
      "claim_id": "claim_001",
      "claim_text": "SGLT2 inhibitors may reduce the risk of major adverse cardiovascular events (MACEs) compared to GLP-1 receptor agonists in patients with type 2 diabetes.",
      "certainty": "low",
      "supporting_snippet_ids": [
        "pubmed_41678006_snip_0",
        "pubmed_41678006_snip_1"
      ],
      "conflicting_snippet_ids": [],
      "limitations": [],
      "grade_rationale": {
        "risk_of_bias": "some concerns in 2/5 studies",
        "inconsistency": "I² = 50%, conflicting results",
        "indirectness": "indirect - populations differ",
        "imprecision": "small sample sizes",
        "publication_bias": "unlikely - comprehensive search"
      },
      "therapeutic_context": "unclassified",
      "studies_supporting": 2,
      "studies_conflicting": 0
    },
    {
      "claim_id": "claim_002",
      "claim_text": "SGLT2 inhibitors may reduce the risk of hospitalizations for heart failure (HF) compared to GLP-1 receptor agonists in patients with type 2 diabetes.",
      "certainty": "low",
      "supporting_snippet_ids": [
        "pubmed_41668999_snip_1",
        "pubmed_41668999_snip_0"
      ],
      "conflicting_snippet_ids": [],
      "limitations": [],
      "grade_rationale": {
        "risk_of_bias": "some concerns in 1/5 studies",
        "inconsistency": "I² = 50%, conflicting results",
        "indirectness": "indirect - populations differ",
        "imprecision": "small sample sizes",
        "publication_bias": "unlikely - comprehensive search"
      },
      "therapeutic_context": "unclassified",
      "studies_supporting": 2,
      "studies_conflicting": 0
    },
    {
      "claim_id": "claim_003",
      "claim_text": "SGLT2 inhibitors may reduce all-cause mortality and cardiovascular-associated mortality compared to GLP-1 receptor agonists in patients with type 2 diabetes.",
      "certainty": "low",
      "supporting_snippet_ids": [
        "pubmed_41668999_snip_1",
        "pubmed_41668999_snip_0"
      ],
      "conflicting_snippet_ids": [],
      "limitations": [],
      "grade_rationale": {
        "risk_of_bias": "some concerns in 1/5 studies",
        "inconsistency": "I² = 50%, conflicting results",
        "indirectness": "indirect - populations differ",
        "imprecision": "small sample sizes",
        "publication_bias": "unlikely - comprehensive search"
      },
      "therapeutic_context": "unclassified",
      "studies_supporting": 2,
      "studies_conflicting": 0
    }
  ],
  "run_kpis": {
    "snippet_coverage": 1.0,
    "verification_coverage": 0.67,
    "claims_with_evidence_ratio": 1.0,
    "total_claims": 3,
    "verified_claims": 2,
    "unverified_claims": 1,
    "is_negative_outcome": false,
    "dod_level": 1
  },
  "composed_hypotheses": [],
  "answer": "The evidence suggests that SGLT2 inhibitors may have a beneficial effect on cardiovascular outcomes compared to GLP-1 receptor agonists in patients with type 2 diabetes. However, the certainty of the evidence is low due to small sample sizes, high risk of bias in some studies, and conflicting results.",
  "metadata": {
    "provider": "openrouter",
    "latency_seconds": 478.8,
    "max_results": 15
  }
}